Diabetes mellitus is a major public health problem, affecting about 10% of the population.
Pharmacotherapy aims to protect against microvascular complications, including blindness …

Aims SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent
semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in …

Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has
been widely appreciated that obesity is a major risk factor for CVD, treatments that produce …

Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …

Introduction FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression
in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

Chronic kidney disease (CKD) affects a 15% of Americans, and diabetic kidney disease
(DKD) is the most common cause of kidney failure. 1, 2 Although the incidence of diabetes …